title: Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
abstract: OBJECTIVE
  To determine the effects on corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab in patients who had NV associated with lipid keratopathy.
  
  
  METHODS
  A case interventional study enrolled 18 patients (18 eyes) with lipid keratopathy. We gave monthly subconjunctival injections of bevacizumab from 3 to 10 times during the follow-up period according to the clinical response. We evaluated the centricity, extent, and percentage of involved corneal surface (PICS) of the corneal NV; the density and PICS of the corneal lipid deposition; and best-corrected visual acuity before and after treatment. We analyzed the treatment effects using Wilcoxon and Student t tests.
  
  
  RESULTS
  After the treatment, the change in best-corrected visual acuity was less than 2 lines. The extent, centricity, and PICS of the corneal NV and the density and PICS of the corneal lipid deposition decreased significantly after treatment (P = 0.014/0.002/0.001 and 0.001/<0.001, respectively). No eyes had side effects.
  
  
  CONCLUSIONS
  The effects of subconjunctival injection of bevacizumab in treating corneal NV associated with lipid deposition were significant in some patients.
authors.affiliation: Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
authors.forename: Hsiao-Sang
authors.initials: HS
authors.lastname: Chu
authors.forename: Fung-Rong
authors.initials: FR
authors.lastname: Hu
authors.forename: Chung-May
authors.initials: CM
authors.lastname: Yang
authors.forename: Po-Ting
authors.initials: PT
authors.lastname: Yeh
authors.forename: Yan-Ming
authors.initials: YM
authors.lastname: Chen
authors.forename: Yu-Chih
authors.initials: YC
authors.lastname: Hou
authors.forename: Wei-Li
authors.initials: WL
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D003228:Conjunctiva; D016510:Corneal Neovascularization / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007267:Injections; D050356:Lipid Metabolism; D052439:Lipid Metabolism Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab